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Background: The interaction of advanced glycation end products (AGEs) and its receptor (RAGE) has played an
important role in the pathogenesis of diabetes and its complications. A soluble form of RAGE (sRAGE) has been
reported as a decoy receptor for AGEs. Oxidative stress is demonstrated in pathological condition such as
atherosclerosis and diabetes mellitus. It has been suggested to be involved in the pathogenesis of both macro- and
microvascular complications. This study was designed to evaluate the effect of glycemic control on sRAGE and
oxidative stress markers in type 2 diabetic patients.
Methods: Seventy patients with type 2 diabetes and 20 healthy subjects were recruited into the study. Blood
glutathione (GSH) and plasma total nitric oxide (NOx) levels were measured using commercially available
colorimetric kits, blood superoxide dismutase (SOD) activity was measured by the method of Marklund and
Marklund, and plasma C-peptide, oxidized LDL (ox-LDL), sRAGE, and VCAM-1 levels were measured using
competitive ELISA kits.
Results: Plasma sRAGE levels were significantly lower (p < 0.05) while VCAM-1 levels were significantly higher
(p < 0.05) in poorly controlled diabetic patients compared with healthy control. Blood GSH levels were significantly
lower in diabetic patients compared with healthy control (p < 0.05). Plasma C-peptide, NOx, ox-LDL levels, and SOD
activity were not significantly different in diabetic patients compared with healthy control. Plasma levels of sRAGE
were negatively associated with circulating VCAM-1 levels in diabetic patients.
Conclusion: Poor glycemic control decreases plasma sRAGE and increases VCAM-1 levels while good glycemic control
improves these abnormalities which provides benefit to diabetic patients.
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Diabetes mellitus (DM) is a complex disease with many
metabolic disorders characterized by hyperglycemia and
defects in insulin secretion or insulin action [1]. Type 2
diabetes mellitus (T2DM) is a global epidemic that
increases in a very rapid way to reach over 300 million
by the year 2025 [2].
The formation of advanced glycation end products
(AGEs), by the so called Maillard reaction, is a complex
process of condensations, rearrangements, fragmentations,
and oxidative modifications which leads to a complicated
network of heterogeneous products [3]. Interaction of
AGEs with their cellular receptors (RAGE) has an import-* Correspondence: mohamed_omar_bio@yahoo.com
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reproduction in any medium, provided the orant role in the pathogenesis of diabetic complications
via enhanced expression of adhesion molecules, including
vascular cell adhesion molecule-1 (VCAM-1) and intercel-
lular adhesion molecule-1 (ICAM-1), as well as increased
vascular permeability and generation of procoagulant
tissue factor [4]. The AGEs action can be neutralized
by usage of soluble RAGE (sRAGE), the extracellular
ligand-binding domain of RAGE, which competes with
RAGE for binding AGEs. It was reported that adminis-
tration of sRAGE in diabetic animals following induction
of diabetes suppressed the vascular changes of accelerated
diabetic atherosclerosis in these animals [5]. However, the
AGE-RAGE interaction is still not clear. There may be
more important ligand for RAGE than AGE-modified
proteins physiologically. S100/calgranulin proteins, highLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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candidate agonists in vivo [6].
Many studies reported increased levels of VCAM-1, one
of the markers of vascular injury, in diabetes mellitus and
might play a role in the changes observed in the vascular
structure of diabetic patients [7,8]. The effect of high
glucose levels on increasing adhesion molecules (ICAM-1
and VCAM-1) have been proved in many studies [9,10].
Oxidative stress is suggested as a mechanism under-
lying diabetes and diabetic complications. Enhanced oxi-
dative stress and changes in antioxidant capacity, found
in both clinical and experimental diabetes, are thought
to be the main cause of chronic diabetic complications
[11]. Excessively high levels of free radicals cause damage
to vital cellular components such as proteins, membrane
lipids, and nucleic acids, and finally lead to cell death [12].
Based on the above considerations, we hypothesized
that tight glycemic control may restore plasma levels of
sRAGE, VCAM-1 and oxidative stress parameters near
the normal level in type 2 diabetic patients. The aims of
the present study were (i) evaluate the effect of glycemic
control on plasma levels of sRAGE, VCAM-1 and some
oxidative stress markers (NOx, ox-LDL, SOD, GSH) in
type 2 diabetic patients, (ii) determine the association
between plasma sRAGE, parameters of oxidative stress
(NOx, ox-LDL, SOD, GSH) and various relevant plasma




This study was conducted in the Out-patient Clinic of
Beni-Suef University Hospital and comprised 90 subjects;
20 healthy control volunteers and 70 patients with type 2
diabetes. All patients submitted to the study underwent
a full medical history, including age, duration of DM
and body mass index (BMI). In addition, blood pressure
measurement and a full medical investigation to screen
for diabetic complications, the presence of cardiovascular
diseases and arteriosclerosis were performed to all patients
enrolled in the study. Electrocardiography and echocar-
diography were performed to all patients and to the
control group that took part in this study. This study
was approved by the local ethical committee of Beni-Suef
University. Full informed consent was obtained from all
participants in the study.
All patients enrolled in the study fulfilled the following
inclusion criteria: age between 40–70 years; receiving
stable antidiabetic therapy (sulfonylureas, metformin,
and/or insulin) for at least 6–8 months and no history of
ketoacidosis.
Exclusion criteria included the following: clinically
significant neurological, hepatic, endocrinologic, or other
major systemic diseases, such as malignancy, elevatedplasma transaminases activity over twice the upper limit
of normal, elevated plasma creatinine concentration
(>1.7 mg/dl) [13], acute major cardiovascular events in
the previous 6 months, presence of acute or chronic
inflammatory diseases, and hormone replacement ther-
apy for women subjected to the study. Exclusion criteria
also included treatment with antineoplastic agents, psy-
choactive agents, glucocorticoids, statins, or vitamin
supplements.
The patients enrolled in the study were classified into
the following groups according to glycemic control;
where the patients were subdivided into good glycemic con-
trol (HbA1c ≤ 7.0%) and poor glycemic control (HbA1c >
7.0%) [14] along with normal subjects: Group 1 (control
group) (C): included 20 age- and BMI-matched healthy
individuals. Group 2: included 28 good controlled dia-
betics (GCD). Group 3: included 42 poorly controlled
diabetics (PCD).
Sample collection
Venous blood samples were withdrawn after overnight
fast from each subject enrolled in the study. Each blood
sample was collected into EDTA-treated tubes and divided
into 2 aliquots. The first aliquot was used for estimation
of blood GSH, glycated hemoglobin (HbA1c), and SOD
activity. The second aliquot was centrifuged at 2000 × g
for 10 minutes to obtain plasma which intern divided into
2 parts; the first part used for estimation of fasting plasma
glucose (FPG) and creatinine levels, and AST and ALT
activities while the second part was stored at −20°C for
subsequent estimation of plasma C-peptide, sRAGE,
VCAM-1, ox-LDL, and NOx levels.
Methods
Determinations of all the parameters were done using
commercially available kits: plasma glucose was measured
by glucose oxidase method (Spinreact, Santa Coloma,
Spain). HbA1c level was measured by cation exchange
resin (BioSystems, Barcelona, Spain). AST and ALT ac-
tivities were measured by kinetic methods (Spinreact,
Santa Coloma, Spain). Creatinine was measured by Jaffé
method (Diamond Diagnostics, Egypt).
GSH was measured by 5,5’-dithiobis(2-nitrobenzoic
acid) (DTNB) method (Biodiagnostic, Giza, Egypt). Deter-
mination of blood SOD activity was based on the method
of Marklund and Marklund [15]. Plasma NOx was mea-
sured by Parameter™ total nitric oxide and nitrate/nitrite
colorimetric assay kit (R&D Systems, Inc., Minneapolis,
USA), plasma C-peptide was determined using ELISA
kit (DRGW, Mountainside, N.J., USA), plasma VCAM-1
and sRAGE were determined using QuantikineW ELISA
kits (R&D Systems, Inc., Minneapolis, USA), and plasma
ox-LDL was measured by competitive ELISA kit (Immun-
diagnostik AG, Bensheim, Germany).
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Shimadzu Double Beam UV-spectrophotometer (Shimadzu,
Japan); while ELISA readings were measured using Tecan
Sunrise microplate reader (Austria).
Statistical analysis
Data are presented as means ± SEM values. The results
were analyzed statistically by one-way ANOVA with
subsequent multiple comparisons using Tukey multiple
comparisons test. Significance level was set at p < 0.05.
Correlations between variables were assessed by Pearson’s
correlation test. All calculations were made using the
computer program SPSS 16.0 (SPSS, Chicago, Ill, USA).
Power calculations between the 3 main groups were
done using PS Power and Sample Size Calculations
Software, version 3.0.43 for MS Windows (William D.
Dupont and Walton D., Vanderbilt, USA).
Results
Clinical characteristics and biochemical changes among
the three studied groups are listed in Table 1. FPG and
HbA1c levels were significantly increased (p < 0.05) in
GCD and PCD compared with C group. Moreover, HbA1c
levels were significantly increased in PCD compared
with GCD.
sRAGE levels were significantly decreased (p = 0.01)
while sVCAM-1 levels were significantly increased (p =
0.006) in PCD compared with C group. On the otherTable 1 Clinical characteristics and biochemical changes amo




Age (years) 51.25 ± 1.51
BMI (kg/m2) 30.00 ± 0.82
Duration of diabetes (years) —
SBP (mmHg) 120 ± 2
DBP (mmHg) 78 ± 1
FPG (mg/dl) 79.50 ± 3.07
HbA1c (%) 5.26 ± 0.08
C-peptide (ng/ml) 4.09 ± 0.30
sRAGE (pg/ml) 804.92 ± 58.14
VCAM-1 (ng/ml) 636.81 ± 30.33
SOD (U/ml) 5.28 ± 0.40
NOx (μmol/l) 177.08 ± 3.81
Ox-LDL (ng/ml) 94.67 ± 4.28
GSH (mg/dl) 45.81 ± 1.01
Antihypertensive therapy, n (%) —
Values are means ± SEM, with the number of patients (n) given in parentheses.
a p < 0.05 versus control healthy group.
b p < 0.05 versus good controlled diabetic patients.
Using one-way ANOVA followed by Tukey post-hoc test.hand, no significant change was observed in these pa-
rameters in GCD when comparing with C group.
No change was found in SOD activity, NOx, ox-LDL,
and C-peptide levels in both diabetic groups when com-
pared with each other or with C group. GSH levels were
significantly decreased (p < 0.05) in both diabetic groups
compared with healthy control.
Univariate analysis revealed a significant positive cor-
relation between fasting plasma glucose and blood
SOD activity in patients with T2DM (r = 0.377, p =
0.001), Figure 1. There was a significant inverse correl-
ation between plasma ox-LDL and blood GSH in
T2DM patients (r = − 0.412, p = 0.00039), Figure 2.
Also, significant inverse correlation was found between
sRAGE and VCAM-1 levels (r = − 0.256, p = 0.032) in
T2DM patients, Figure 3. Additionally, there was a
significant positive correlation between BMI and C-
peptide levels in T2DM patients (r = 0.330, p = 0.005),
Figure 4.
To evaluate the relationship between sRAGE and clin-
ical and biochemical parameters, a multivariate linear
regression analysis was performed in which sRAGE was
included as the dependent variable. All variables listed
in Table 1 were considered as independent variables.
The significant predictors of sRAGE were VCAM-1 (β = −
0.259, p = 0.044) in diabetic patients (R2 = 0.24) and
VCAM-1 (β = − 0.274, p = 0.013), and BMI (β = − 0.335,
p = 0.007) in all study subjects (R2 = 0.257).ng the three studied groups
controlled diabetic patients
(GCD) (28)
Poorly controlled diabetic patients
(PCD) (42)
13/15 10/32
56.39 ± 1.43 54.00 ± 1.17
31.72 ± 0.77 32.02 ± 0.52
7.82 ± 0.76 10.48 ± 1.01
129 ± 2a 130 ± 2a
82 ± 1a 81 ± 1a
155.11 ± 13.01a 191.02 ± 13.04a
6.15 ± 0.10a 8.71 ± 0.57a,b
4.46 ± 0.25 4.13 ± 0.24
630.47 ± 48.14 600.06 ± 37.75a
739.69 ± 32.26 808.84 ± 36.90a
7.44 ± 0.67 6.77 ± 0.61
178.65 ± 4.04 187.15 ± 2.84
96.78 ± 6.59 114.31 ± 8.05
41.10 ± 1.34a 39.57 ± 0.98a
12(43) 22(52)
Figure 1 Correlation between FPG level and SOD activity in
T2DM patients (r = 0.377, p = 0.001, n =70).
Figure 3 Correlation between sRAGE and VCAM-1 levels in
T2DM patients (r = − 0.256, p = 0.032, n =70).
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As reported by many studies [16,17], our study found
decreased sRAGE level in PCD compared with healthy
control. On the other hand, other studies [18,19] found
higher level of sRAGE in T2DM compared with control
subjects. Tan et al. [18] reported higher serum sRAGE
levels in T2DM with proteinuria; while patients with
normoalbuminuria or microalbuminuria showed no sig-
nificant difference compared with normal controls. Also,
Kaňková et al. [20] found increased sRAGE levels in
patients with diabetic nephropathy (DN) than normo-
albuminuric patients and reported that glomerular filtra-
tion rate was the principal determinant of sRAGE
levels in diabetic subjects with DN. In the present
study, our result is partially consistent with the previous
studies regarding GCD group which showed no significant
change compared with normal control but PCD showed
significant decrease in sRAGE levels. Although, all diabeticFigure 2 Correlation between GSH and ox-LDL levels in T2DM
patients (r = − 0.412, p = 0.00039, n =70).patients in the present work had a normal kidney function,
PCD had a significant decrease in sRAGE levels. Thus,
poor glycemic control may decrease sRAGE level or
influence its consumption. Devangelio et al. [16] found
an increase in sRAGE levels after improvement of gly-
cemic control and suggested that levels of sRAGE may
be reduced due to excessive binding to circulating AGEs
ligands. Moreover, increased ligand burden may consume
all existing sRAGE and/or endogenous mechanisms
that release sRAGE may be impaired [21] which may
explain decreased levels of sRAGE in PCD group in the
present work.
Many studies reported elevation of VCAM-1 levels in
T2DM compared with control subjects [9,22,23]. In the
present study, results of VCAM-1 in PCD are consistent
with these previous studies. Poor glycemic control and
increased glucose levels may be responsible for signifi-
cant higher levels of VCAM-1 in PCD. Morigi et al.Figure 4 Correlation between BMI and C-peptide levels in
T2DM patients (r = 0.330, p = 0.005, n =70).
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ICAM-1, and E-selectin in human umbilical vein endo-
thelial cells (HUVEC) and found elevation of these
parameters as well as increased leukocyte adhesion in
HUVEC. Also, hyperglycemia leads to increased produc-
tion of AGEs which stimulates vascular inflammation
and VCAM-1 expression [25]. Thus, increase in AGEs
formation in PCD due to poor glycemic control may
explain significant elevation of VCAM-1 levels in this
group but not in GCD in the present study. Moreover,
sRAGE, which is important in capture of AGEs and
prevent effect of AGEs on signaling and alteration of
cellular properties [26], is significantly decreased in
PCD but not in GCD which may emphasize the previous
hypothesis that increased AGEs levels in PCD causes
elevation of VCAM-1. It is worth to mention here that
an inverse correlation between sRAGE and VCAM-1
levels was found for the first time in the present study
which may suggest a protective role of sRAGE against
vascular inflammation. On the other hand, Boulbou
et al. [7] found no change in VCAM-1 levels in T2DM
patients compared with healthy control. This discrepancy
between studies in VCAM-1 levels may be due to dif-
ferences in number of patients, glycemic control, and
ethnic groups.
The present study is in agreement with previous ob-
servations [27-29] showing unchanged SOD activity in
DM patients. On the other hand, some authors reported
both increased [11,30] or decreased [31] SOD activity in
diabetic patients compared with control subjects. Chen
et al. [32] found a significant decrease in SOD activity in
newly diagnosed T2DM patients compared with controls
which increased significantly after 3-month treatment
with gliclazide. It is possible that changes in SOD activ-
ity may occur in early stages of diabetes as found by
Chen and coworkers. Patients in the present study had
had diabetes for relatively long time and had been on
long-standing hypoglycemic agents which may be a pos-
sible explanation for unchanged SOD activity in these
patients. Komosińska-Vassev et al. [33] found significant
higher SOD activities in T2DM patients and the greatest
increase was found in poorly controlled diabetics with
micro- and macrovascular complications. In the present
study, patients were free of complications which may be
another explanation for unchanged SOD activity. Treat-
ment with different hypoglycemic agents may also influ-
ence SOD activity. Gliclazide treatment was proven to
enhance SOD activity in T2DM due to its antioxidant
properties, and so prevents consumption of SOD by free
radicals [34]. Metformin also proved to increase erythro-
cyte SOD activity after 4 weeks treatment in T2DM [35].
Studies reported that NOx levels decrease [36,37], in-
crease [38,39], or unchanged [40,41] in T2DM patients
compared with control subjects. Our results regardingNOx levels are consistent with studies that found un-
changed levels compared with healthy controls. Tatsch
et al. [37] found decreased serum NOx in T2DM and
suggested that increased formation of O2
•– during oxida-
tive stress in vascular wall may inhibit NO-mediated
endothelial function by formation of peroxynitrite. In
the present study, no change in SOD activities were
found in the diabetic groups from controls which may
protect NO• from deleterious O2
•– and so, NOx levels
in diabetic patients did not differ from that of normal
control.
Many studies reported increased LDL oxidation in
T2DM [42-44]. On the other hand, Hamed et al. [45]
found that plasma ox-LDL levels in T2DM without cor-
onary artery disease were not significantly different when
compared with healthy control. Our result is consistent
with that of the previous study as our patients were free
of complications. Another explanation for unchanged
ox-LDL levels in diabetic patients in the present study
may be due to the treatment with sulfonylureas, insulin
and/or metformin which have antioxidant effects. Insulin
was reported for its antioxidant effect as it suppressed
LDL oxidation when given to T2DM patients [46]. Sulfo-
nylureas have also been reported for its antioxidant
effect, but this was demonstrated for gliclazide only
[34,47] not all members of sulfonylurea group of com-
pounds. Fortunately, most of patients in the present study
were on gliclazide treatment which may account for
unchanged ox-LDL levels in these patients. Treatment
of patients with metformin may also participate in pro-
tection of LDL from oxidation. Many studies reported
antioxidant effect of metformin [48,49].
Many previous studies reported decreased GSH levels
in diabetic patients compared with normal control
[35,50,51]. Our results are in agreement with these
studies. Decreased GSH levels in DM patients may be
caused by different pathways including increased activity
of sorbitol pathway which depletes NADPH, so limits
the reduction of GSSG to GSH; decreased activity of
glucose-6-phosphate dehydrogenase in hexose monophos-
phate shunt in DM which generates NADPH; and passage
of GSSG via erythrocyte membrane which inhibits its
reduction to GSH [36]. Another cause for lower GSH
levels in DM may be the decreased levels of amino
acids necessary for GSH synthesis; L-cysteine, L-glutamate,
and L-glycine [52]. Many studies have reported decreased
levels of theses amino acids in DM [53,54].
Regarding C-peptide, our result is in agreement with
previous study [55] reported unchanged C-peptide levels
in type 2 diabetes compared with normal controls. C-
peptide is secreted in equimolar amounts along with
insulin and is not extracted by the liver. Therefore, C-
peptide can be used as indirect measurement of β-cell
function [56]. Treatment of diabetic patients with ex-
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a result of reduction in blood glucose [57]. Only 20
patients (28.6%) in the present study were treated with
insulin and the rest were treated with sulfonylurea and/
or metformin which may explain normal C-peptide
levels in these patients. Chan et al. [58] found that BMI
was positively correlated with C-peptide levels in type 2
diabetic patients and that obese patients had highest C-
peptide levels while lean patients had the lowest level.
Our results are consistent with that of Chan and co-
workers as we found positive correlation between C-
peptide levels and BMI. Most of patients (49/70; 70%)
in the present study are obese as defined by BMI >
30 kg/m2 [59] which may be another explanation for
normal C-peptide level in these diabetic patients.
A limitation of this study is that the sample sizes were
relatively small and unequal among the groups. With
samples of a larger population, some of the non-signifi-
cant differences may have reached statistical significance.
However, the post-hoc power analysis indicated that the
current number of controls and patients was sufficient
to detect a significant correlation between variables.
Assuming a type I error of 5% and a power of 95%, the
minimum association that could be detected was r = 0.248.
Brown and Fraser [60] and Wittwer et al. [61] reported
that sRAGE has marked individuality and variation even
in healthy subjects, which may be attributed to metabolic
differences that are not necessarily linked to any pathology
and showed that sRAGE may be useful for intra-individual
monitoring or for risk assessment for a given pathology
but less efficient as a screening marker for any disease.
This makes another limitation of our study especially
with the present small sample sizes of the study groups.
Actually, future studies with larger cohorts are needed
to clarify these issues.
Conclusion
In conclusion, in type 2 diabetic patients, free of compli-
cations, poor glycemic control decreases plasma sRAGE
and increases VCAM-1 levels while good glycemic con-
trol improves these abnormalities which provides benefit
to diabetic patients. The study demonstrated for first
time that plasma levels of sRAGE is inversely correlated
with plasma levels of VCAM-1 which may suggest a
protective role of sRAGE against vascular inflammation
in type 2 diabetes. Also, the use of certain hypoglycemic
drugs with antioxidant properties in treatment of type
2 diabetes may provide benefit via reduction of oxida-
tive stress. Further studies are needed to investigate as-
sociations between sRAGE and various relevant plasma
factors as well as diabetic complications.
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